Billingham, UK, January 31, 2019 ‒ FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the inception of the “FDB Centre of Excellence in Bioprocessing 2.0.” (CEB) in the United Kingdom. This initiative is an extension of Fujifilm’s global innovation initiatives.
The Centre of Excellence will be led and funded by Fujifilm Diosynth Biotechnologies, in partnership with leading academic institutions – University of Edinburgh; and University of Manchester, and University of York. This initiative was jointly defined by Fujifilm and CEB Partners to address challenges and opportunities in bioprocessing.
“Fujifilm has historically supported a significant number of innovation projects globally. The FDB Centre of Excellence in Bioprocessing 2.0 builds on Fujifilm’s historical support of research here in the United Kingdom and allows us to develop long term partnerships with these world class universities to support the growth of our business,” said Andy Topping, chief scientific officer at Fujifilm.
Formal announcement of the establishment of the CEB took place at the Industrial Biotechnology Innovation Centre (IBioIC) Annual Conference 2019, ‘Industrial Biotechnology for a Sustainable Future’, which was held this past 30 and 31st of January 2019 at the Technology Innovation Centre, Glasgow. The IBioIC’s Annual Conference is the leading general IB conference in the UK. The conference celebrates the success of the biotechnology industry in the United Kingdom and provides delegates with networking opportunities needed to drive new collaborations. Fujifilm is a core member of the IBioIC, which provides access to funding, events and access to other companies within its network.
“Our aim is to link fundamental research and world class expertise to the business needs of Fujifilm,” said Jen Vanderhoven, Vice President of global business change. “We are creating an innovation engine that drives new processes, efficiencies, products and services.”
CEB related activities will commence in 2019.
FUJIFILM Diosynth Biotechnologies an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Billingham and Redcar, UK, RTP, North Carolina and College Station, Texas. FUJIFILM Diosynth has over twenty five years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com
FUJIFILM Holdings Corporation, Tokyo, Japan brings cutting-edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2018, the company had global revenues of $23.0 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
All product and company names herein may be trademarks of their registered owners.
FUJIFILM Diosynth Biotechnologies
Tel: +44 (0) 1642 36 7363